|

ONT01 is a small molecule CD11b modulator. Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Early 1: 1

Top Sponsors

  • Hospital for Special Surgery, New York1

Indications

  • Systemic Lupus Erythematosus (Disorder)1
  • Lupus Nephritis - World Health Organization (WHO) Class III1
  • Lupus Nephritis - WHO Class IV1
  • Lupus Nephritis - WHO Class III1
  • Lupus Nephritis (LN)1

New York, New York1 trial

Safety and Efficacy of ONT01 in Lupus

Hospital for Special Surgery

Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.